F 15599

Drug Profile

F 15599

Alternative Names: F15599; NLX-101

Latest Information Update: 25 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pierre Fabre
  • Developer Neurolixis
  • Class Antidementias; Antidepressants; Antipsychotics; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rett syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cognition disorders; Mood disorders; Rett syndrome; Schizophrenia

Most Recent Events

  • 25 Jun 2015 Neurolixis is planning a phase I trial in Rett Syndrome in USA
  • 21 Apr 2015 F 15599 is available for licensing as of 21 Apr 2015 (http://www.neurolixis.com/en/)
  • 06 Mar 2014 F 15599 receives Orphan Drug status for Rett syndrome in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top